In addition, lenvatinib reactivates interferon-gamma signaling in tumor cells by inhibiting fibroblast growth factor receptor (FGFR) (28) and enhances its combined antitumor activity with anti-PD-1 antibodies by blocking FGFR4 to reduce tumor PD-L1 levels and Treg differentiation (29). This evidence concerns the gene FGFR4 and neoplasm.